Relafen 750, the drug, represents a noteworthy advancement within biochemical pharmacy , offering a unique mechanism of action . This primary result is blocking prostaglandin synthesis , specifically targeting COX-2 . This selective inhibition allows symptom management with potentially minimizing the digestive risk linked with conventional NSAIDs.